Sublingual desmopressin is efficient and safe in the therapy of lithiasic renal colic

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

To evaluate the effects of newer sublingual desmopressin administration in lithiasic renal colic, alone or combined with a nonsteroidal anti-inflammatory drug (NSAID).

Who Took Part

The study group was 249 patients.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Patients experiencing pain aggravation were rescued and excluded from the study.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Vasopressin study one party knew the assignments and the other did not.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

Pain intensity was assessed using the visual analogue scale before and thirty minutes after drug administration.

What Was Measured

The subject headings attached to it are Administration, Sublingual, Anti-Inflammatory Agents, Non-Steroidal, Antidiuretic Agents, Deamino Arginine Vasopressin, Nephrolithiasis, Pain Measurement and Renal Colic.

Author keywords: Desmopressin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Vasopressin and Desmopressin in 249 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (International urology and nephrology), a journal based in Netherlands.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.